Temporary cessation of ibrutinib results in reduced grade 3‐4 infections and durable remissions—Interim analysis of an on‐off‐repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia
Open Access
Abstract
Ibrutinib is used continuously in CLL. This phase 1b/2 study interim analysis explored on-off-repeat dosing to reduce toxicity. After 12 months, 16/22 patients (73%) remained in first off-phase irrespective if initial CR/PR or TP53 aberration. Grade 3-4 infections were reduced from 55% to 5% during a similarly long off-phase (P < .01). Treg and exhausted T-cells increased (P = .01). Six patients restarted ibrutinib at early progression and remain drug-sensitive. Our interim analysis shows a durable off-phase in most patients, with reduced infections and cost-saving potential. If toxicity-driven permanent cessation of ibrutinib will be affected will be explored in the extended study.Keywords
This publication has 14 references indexed in Scilit:
- Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease‐negativity in the bone marrow of poor‐prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections – Results from a phase I studyBritish Journal of Haematology, 2017
- Frequency and functional characterization of exhausted CD8+ T cells in chronic lymphocytic leukemiaEuropean Journal of Haematology, 2017
- T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markersHaematologica, 2016
- Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpointsCancer Immunology, Immunotherapy, 2016
- Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studyThe Lancet Oncology, 2016
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia GroupHaematologica, 2016
- Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinibBlood, 2015
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2013
- T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine productionBlood, 2013
- Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)Blood, 2002